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 ABSTRACT  
Dendrimers are emerging as potential non-viral vectors for efficiently delivering drugs 
and nucleic acids to the brain and cancer cells. These polymers are highly branched, 
three-dimensional macromolecules with modifiable surface functionalities and 
available internal cavities that make them attractive as delivery systems for drug and 
gene delivery applications. This review highlights the recent therapeutic advances 
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INTRODUCTION   
Treatment of brain diseases and cancer represent major therapeutic challenges in 
PRGHUQPHGLFLQH&HUHEUDOGLVHDVHVVXFKDV$O]KHLPHU¶VDQG3DUNLQVRQ¶VGLVHDVHV
DIIHFW D ODUJH SHUFHQWDJH RI WKH ZRUOG¶V SRSXODWLRQ DQG KDUGO\ UHVSRQG WR
intravenously administered, small molecule treatment [1,2]. In addition, cancer 
remains one of the leading causes of mortality, accounting for 8.2 million deaths in 
2012.  
Recent advances in multi-disciplinary research have led to the discovery of 
numerous promising drugs against cerebral diseases and cancer.  However, most of 
these drugs fail to specifically reach the pathological site, resulting in secondary 
effects on healthy tissues. In order to remediate this problem, it is therefore crucial to 
be able to deliver these drug candidates specifically to their site of action. 
In this context, dendrimers are emerging as potential non-viral vectors for efficiently 
delivering drugs and nucleic acids to the brain and cancer cells. They are polymeric 
molecules with perfectly branched multiple monomers that emerge radially from a 
central core similar to a tree (dendron in Greek) [3]. Their modifiable surface 
functionalities and available internal cavities make them attractive as delivery 
systems for drug and gene delivery applications. (For comparison of the advantages 
and inconvenients of dendrimers with other delivery systems, please refer to 
reference [4]). These symmetrical molecules can be synthesized to a definite size in 
a reproducible manner to form spherical macromolecules, as initially described by the 
Vögtle group in the late 1970s [5], the Tomalia group and the Newkome group in the 
1980s [3,6-8]. The dendrimers can be synthesized by mainly two methods, the 
Tomalia-type divergent synthesis, in which the dendrimer is formed in a step-wise 
manner from the core to the periphery [9] and the Fréchet-type convergent synthesis, 
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in which the dendrons are synthesized first and then anchored to a multi-functional 
core [10].  
Dendrimer can be divided into three structural domains:  
D multivalent surface which has been largely exploited by many investigators as a 
means to achieve the conjugation of targeting moieties and the binding of drugs or 
nucleic acids for therapeutic applications. 
dendrons delimitating void spaces shielded by the surface. This domain has been 
used for the encapsulation of various chemically sensitive drugs. 
Whe core which allowed the attachment of the dendrons [11] (Figure 1).   
Each of these three parts can be tailored for a desired function of the dendrimers 
such as drug delivery, molecular sensors, enzyme mimics and bioimaging (Figure 2). 
This review will mainly focus on the recent therapeutic advances made using 
dendrimers for brain targeting and cancer therapy. (For further reading about 





1. DENDRIMERS FOR BRAIN DELIVERY 
Diseases of the central nervous system (CNS), such as $O]KHLPHU¶V GLVHDVH
+XQWLQJWRQ¶VGLVHDVH3DUNLQVRQ¶VGLVHDVHDQG brain cancer currently stand for 11 % 
of the global burden of disease. The number of new drugs approved for the treatment 
of CNS disorders remains very low due to their inability to cross the blood-brain 
barrier (BBB), a key regulating site for drug access to the brain which acts as an 
entrance gateway for various nutrients to the brain while protecting it from potentially 
toxic compounds [1-2]. The barrier function of BBB is a combination of physical 
barrier, transport barrier and metabolic barrier [15]. The low and selective 
permeability of BBB can be credited to its unique biological properties:  
the lack of fenestrations, vesicular transport and pinocytosis in the endothelial cells 
[16,17].  
 the physical barrier due to the presence of tight junctions between adjacent 
endothelial cells [18].  
the transport barriers resulting from the expression of various transporters including 
Glucose transporter 1 (GLUT-1), L-type amino acid transporter (LAT1), transferrin 
receptors (TfR), insulin receptors, low density lipoprotein receptor- related proteins 
(LRP1 and LRP2), and ATP family of efflux transporters such as p-glycoprotein (P-
gp) and the multidrug resistance-related proteins (MRP). These transporters and 
receptors expressed on the capillary endothelial cells of the BBB only carry specific 
molecules to / from the brain [19].  
the enzymatic barrier of degrading enzymes localized in endothelial cells. 
 
Although the multi-tasking BBB plays an essential role in the development of CNS as 
a complex integrated network, it poses a major problem for treatment strategies that 
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require the delivery of drugs and nucleic acids to the brain for the treatment of CNS 
disorders. This issue can however be overcome by exploiting the specific transport 
systems expressed on the BBB for the transport of therapeutics to the brain. Various 
dendrimers based on this delivery strategy have been developed and preclinically 
evaluated. Among other nanomaterials, they appear to be particularly promising in 
this application due to the various advantages they offer, such as monodispersity, 
lack of immunogenicity, permeation through biological barriers, improved drug 
stability and maintenance of drug levels in the therapeutically desirable range [11].  
 
1.1 Dendrimers for transferrin receptor targeting 
Out of all the tissues in the body, the expression of the TfRs is mainly found on the 
brain capillary endothelium which forms the BBB [20]. TfR is responsible for the 
transport and distribution of iron in the body through an iron-binding glycoprotein, 
transferrin (Tf). Since the last two decades, Tf has been extensively investigated as a 
targeting ligand for the drug and gene delivery systems to transport therapeutics to 
the brain [21]. 
Due to their unique physico-chemical properties, dendrimers have been shown to be 
promising candidates for brain delivery. Polyamidoamide (PAMAM) dendrimer 
(Figure 3) is the most researched candidate for the delivery of the therapeutics to 
brain via TfR targeting. In a study by Huang and colleagues [22], PAMAM (G5) was 
conjugated to Tf through a bifunctional polyethyleneglycol (PEG) spacer and 
complexed to a plasmid DNA encoding green fluorescent protein (GFP). After 
intravenous administration to mice, PAMAM-PEG-Tf/DNA was found to be able to 
cross the BBB, as demonstrated by a body distribution study of 125I-labelled 
dendrimers. Qualitative analysis demonstrated GFP expression in several brain 
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areas such as the cortical layer, hippocampus, caudate putamen, substantia nigra 
and the 4th ventricle. This gene expression was about 2-fold higher compared to the 
PAMAM/DNA and PAMAM-PEG/DNA complexes.  
Following the discovery that wheat germ agglutinin (WGA) was a promising ligand for 
increasing drug uptake to the brain [23], and binding to cancer cells [24], a dual 
targeting nanocarrier, PEGylated PAMAM (G4) conjugated to Tf and WGA on the 
periphery and loading doxorubicin (DOX) in its interior was synthesized. Due to its 
dual targeting effect, this delivery system led to an increased transport ratio of 13.5 % 
in an in vitro model of BBB, compared to 8 % for PAMAM-PEG-WGA, 7 % for 
PAMAM-PEG-Tf and 5% for free DOX. Moreover, this dual targeted dendrimer-based 
therapeutic system decreased the viability of C6 glioma cells in a brain microvascular 
endothelial cells (BMVEC)/C6 glioma co-culture model. The viability of C6 glioma 
cells was 14.5 % in comparison with 21.3 % for PAMAM-PEG-Tf-DOX, 23.7 % for 
PAMAM-PEG-WGA-DOX and 22.4 % for free DOX [25]. 
Multidrug resistance proteins, consisting of a family of ATP-binding cassette (ABC) 
proteins such as P-glycoprotein (P-gp), are expressed not only on the endothelial 
cells of the BBB but also on glioma cells. They function as efflux transporters, 
restricting drug transport across the BBB and prohibiting cellular uptake by glioma 
cells [26,27]. Tamoxifen (TAM), an estrogen receptor antagonist, has the ability to 
inhibit the multidrug resistance proteins and thus improve BBB transport [28,29]. 
Based on this, Li et al. [30] synthesized a pH-sensitive nanocarrier, consisting of 
PAMAM (G4) conjugated to Tf on the exterior and encapsulating TAM with a loading 
efficacy of 27 drug molecules per dendrimer molecule. DOX was also peripherally 
linked to the peripheral amino groups of PAMAM through an acid labile hydrazone 
bond, with a conjugation efficacy of 7-8 doxorubicin molecules per dendrimer 
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molecule. In an in vitro model of BBB, PAMAM-DOX-PEG-Tf-TAM resulted in an 
increased DOX transport ratio of 6.1%, compared to 4.9% for PAMAM-DOX-PEG-Tf 
and 4.6% for PAMAM-DOX-PEG. This targeted dendrimer-based therapeutic system 
also decreased the viability of C6 cells in a BMVEC/C6 glioma co-culture model.  The 
viability of C6 glioma cells was 68.8% for PAMAM-DOX-PEG-Tf-TAM, reduced 
compared to that observed with other treatments (76.1% for PAMAM-DOX-PEG-Tf 
and 83.9 % for PAMAM-DOX-PEG).  
Another dendrimer, polypropylenimine (PPI) (Figure 3), is a promising alternative to 
PAMAM for gene delivery to the brain and cancer cells. Initial studies by Kabanov 
and colleagues [31] demonstrated that this dendrimer binds to DNA via electrostatic 
interactions involving only the peripheral amine groups, allowing the tertiary amine 
JURXSVSUHVHQWLQVLGHWKHGHQGULPHUWRDFWDV³SURWRQVSRQJH´LQWKHHQGRVRPHIn a 
recent study, we demonstrated that the intravenous injection of transferrin-bearing 
PPI dendriplex more than doubled the gene expression in the brain compared to the 
unmodified dendriplex, while decreasing the non-specific gene expression in the 
lung. Gene expression was at least 3-fold higher in the brain than in any tested 
peripheral organs and was at its highest 24h following the injection of the treatments. 
These results suggest that transferrin-bearing polypropylenimine dendrimer is a 
highly promising gene delivery system to the brain [32]. 
 
1.2. Dendrimer-based low density lipoprotein receptor-related proteins (LRP1 & 
LRP2) targeting 
Low density lipoprotein receptor-related proteins (LRP1 and LRP2) are multi-
functional scavenger receptors expressed on the BBB. They have an ability to bind to 
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a range of molecules, including proteinases, proteinase-inhibitor complexes and 
lipoprotein lipase-enriched lipoproteins, and make them cross the BBB [33]. 
Lactoferrin (Lf) is a single chain cationic iron-binding protein belonging to the Tf 
family. Lf is capable of crossing the BBB through binding to LRP receptors [34]. 
Taking advantage of this ability, Huang and colleagues [35] synthesized a non-viral 
brain-targeted gene delivery system consisting of PAMAM (G5) conjugated to Lf via a 
PEG spacer and complexed to a plasmid DNA encoding green fluorescent protein 
(GFP). Following intravenous administration of PAMAM-PEG-Lf/DNA in mice, GFP 
expression was observed in the cortical layer, hippocampus, caudate putamen, 
substantia nigra and fourth ventricle of the animals. This gene expression was 5.2-
fold higher compared to that of PAMAM-PEG/DNA and PAMAM/DNA. In addition, the 
authors demonstrated that both LRP receptor and adsorptive-mediated mechanisms 
contributed to the higher uptake of the PAMAM-PEG-Lf/DNA in the brain capillary 
endothelial cells [36].  
Angiopeps, a family of peptides derived from Kunitz domains of the drug aprotinin 
and other proteins, are highly effective brain targeting ligands. They are transported 
across the BBB through LRP1-mediated transcytosis [37]. Angiopep-2 was 
conjugated to PAMAM through a specific reaction with the terminal N-
hydroxysuccinimidyl of the bifunctional PEG derivative. After intravenous 
administration of PAMAM-PEG-Angiopep complexed with a plasmid DNA encoding 
GFP, the brain uptake of DNA was up to 8.4-fold higher than with PAMAM/DNA in 
mice. Gene expression in brain was observed in the cortical layer, caudate putamen, 
hippocampus and substantia nigra. Both LRP-mediated endocytosis and adsorptive 
endocytosis contributed to the mechanism of cellular uptake of PAMAM-PEG-
Angiopep [38]. In another study, Angiopep was conjugated to the dendrigraft poly-L-
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lysine (DGL) (G3) via a PEG linkage and complexed to a plasmid DNA encoding 
Human Glial-Derived Neurotrophic Factor (hGDNF), to evaluate its neuroprotective 
effect in a 3DUNLQVRQ¶V GLVHDVH model. The DGL-PEG-Angiopep/hGDNF not only 
exhibited a higher cellular DNA uptake and gene expression in brain cells compared 
to the unmodified DGL, but also improved the locomotor activity and recovery of the 
dopaminergic neurons [39].  
 
1.3. Dendrimer based glucose transporter (GLUT-1) targeting 
Glucose transporter GLUT-1 is abundantly expressed on the blood-brain barrier for 
transporting optimal levels of glucose to the brain for its normal functioning [40]. 
Based on this, Dhanikula and colleagues [41] synthesized polyether-copolyester 
(PEPE) dendrimers (G2) conjugated to D-glucosamine via carbamate linkage and 
loaded with up to 20.8% w/w methotrexate (MTX) for the treatment of gliomas. As 
GLUT-1 is also expressed on brain tumors, the glycosylation of the MTX-loaded 
PEPE dendrimers not only enhanced the drug transport across the BBB compared to 
the free MTX but also allow the of high amounts of MTX in the central necrotic 
regions of the avascular brain tumor spheroids.  
 
1.4. Other dendrimer based targeting strategies 
Leptin, a 146 amino acid polypeptide, is secreted in the blood by the adipocytes in 
response to the food intake and acts to regulate appetite and retard weight gain. 
Leptin receptors are present on the luminal side of the brain microvessels and on the 
choroid plexus [42]. Exogenous leptin cannot be used as a targeting ligand for brain 
uptake, as the leptin receptors are saturated at very low concentrations (0.15-5 ng/ 
ml) of the endogenous leptin. However peptide fragments derived from leptin contain 
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important sequences for leptin receptor binding on the BBB. Amongst them, the 
sequence 61-90 (leptin 30) is taken up by the brain and shows equivalent brain 
concentration as its parent molecule leptin [43]. Based on this result, the dendrigraft 
poly-L-lysine (DGL) was conjugated to leptin 30 through a PEG spacer and evaluated 
for gene delivery to the brain. After intravenous administration of DGL-PEG-Leptin30 
complexed to a plasmid DNA, the gene expression was higher than that of DGL-
PEG/DNA and DGL/DNA. It was observed mainly in cortical layer, hippocampus, 
caudate putamen and substantia nigra [44].  
Magnetic delivery systems have been widely investigated for the targeted delivery of 
therapeutics. Han and colleagues [45] synthesized a novel brain-targeted bi-
functional gene delivery system based on natural magnetic particles, called 
magnetosomes (MS), and combining the brain delivery effects of an external 
magnetic field and a cell-penetrating peptide. To this end, they conjugated MS to 
PAMAM and to a cell penetrating peptide, the transactivating transcriptional activator 
(Tat) protein. After intravenous administration of radiolabelled Tat-MS-PAMAM and 
MS-PAMAM, followed by the application of an external magnetic field for 25 min, Tat-
MS-PAMAM exhibited a 2-fold brain uptake increase compared to MS-PAMAM. 
Without magnetic field, this brain uptake fell by 1.88-fold. However, it was not 
possible to evaluate the direct role played by TAT grafting and the magnetosomes in 
this brain delivery increase, due to the absence of PAMAM-DNA testing in this study. 
 
The use of overexpressed receptors/transporters on the BBB to facilitate the uptake 
of DNA or drugs to the brain can however be limited by the non-specific presence of 
receptors/ transporters on other tissues. For example, Tf can recognize both TfR1 
and TfR2, but has a much higher affinity for TfR1 (25-fold higher) [46]. TfR1 is 
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expressed at low levels in most human tissues, but also at high levels on the 
vascular endothelium of brain capillaries [20]. In addition, its levels of expression on 
cancer cells are up to 100-fold higher than those on normal cells [47], making this 
receptor a promising target for the delivery of therapeutics to the brain and cancer 
cells.  In comparison, TfR2 is mostly expressed on hepatocytes and on a wide range 
of tissues but at very low levels [46]. Although the risk of non-specific delivery of 
therapeutics to the liver and other normal tissues exists, it is therefore very limited 






2. DENDRIMERS FOR CANCER THERAPY 
1.1. Drug delivery 
Dendrimer-based drug delivery systems have been developed in order to improve 
the biodistribution of a drug in the body and to allow the controlled release of the drug 
at its target site. Their high aqueous solubility, low toxicity, compact globular shape 
and controlled surface functionalities made them ideal carriers for anti-cancer drugs 
[11]. Dendrimers can also facilitate passive targeting of anti-cancer drugs to tumor 
tissue. This selective accumulation of macromolecules in tumorsWHUPHG³HQKDQFHG
SHUPHDELOLW\DQG UHWHQWLRQ (35HIIHFW´ is the consequence of the combination of 
reduced lymphatic drainage and increased permeability of tumor vasculature to 
macromolecules [48].   
Dendrimers can either non-covalently encapsulate drugs in the void spaces within 
the dendritic structure, or carry them via covalent conjugation to the surface groups.   
 
1.1.1. Encapsulation of drugs within the dendrimers 
The internal cavity of the dendrimers could be used for the encapsulation of anti-
cancer drugs, offering the advantage of subsequent controlled release of the drug to 
the tumors. Another less frequently used encapsulation strategy is to entrap anti-
cancer drugs by micellar formulation of dendrimers. 
Small hydrophobic anti-cancer drugs are generally entrapped in the dendrimers. 
Their solubility and toxicity against cancer cells have been shown to be increased by 
encapsulation within dendrimers (G4 to G6) [14]. 




Camptothecin has its anti-cancer efficacy limited by its low water solubility and 
secondary effects on normal tissue, including bladder inflammation. To overcome this 
limitation, 10-hydroxycamptothecin has been encapsulated in a poly (glycerol 
succinic acid) (G4) dendrimer at a concentration of 120 µM, which corresponded to a 
20-fold increase in drug solubility in water compared to that of the unencapsulated 
drug (6 µM) [49]. Treatment of a panel of cancer cells with the drug-loaded dendrimer 
resulted in a decrease of IC50 compared to free drug in DMSO for all the cell lines 
tested, by up to 7.1-fold in MCF-7 breast carcinoma [50]. This improved anti-cancer 
effect resulted from the faster internalization of the drug encapsulated in the 
dendrimer, with intracellular concentration 16-fold higher than the free drug after 2 h 
treatment incubation.  Retention time of the drug carried by dendrimers was also 
longer compared to free drug in solution (respectively 50% and 35% 10 h after the 
start of the treatment) [50].   
 
 Cisplatin 
Another drug, cisplatin, also has its anti-cancer therapeutic effect limited by its poor 
water solubility as well as the development of drug resistance by some cancer cell 
lines. The encapsulation of cisplatin in PAMAM dendrimer (dendrimer-Pt : 20-25 wt 
% platinum) resulted in an increase accumulation of the drug in B16F10 melanomas 
as a result of the passive targeting of tumor tissues due to the EPR effect and 
decreased the toxicity on normal tissues by 3-to 15-fold compared to the free drug in 
solution, in a murine model [51].  
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 Doxorubicin 
To increase drug solubility in water and decrease its secondary effects in healthy 
tissues, doxorubicin was encapsulated in PEGylated PAMAM dendrimers (G3 and 4). 
The authors of this study demonstrated that the dendrimer size and PEG chain 
length have a major impact on the encapsulation efficacy of the drug, with PAMAM 
dendrimer (G4) and PEG 2000 leading to the highest drug encapsulation of 6.5 
doxorubicin molecules per dendrimer molecule [52].  
In another study, PAMAM dendrimer (G4) loaded with doxorubicin at a doxorubicin to 
PAMAM molar ratio of 3.56 ± 0.04 was then encapsulated in liposomes. This 
³3$0$0-GR[RUXELFLQ LQ OLSRVRPHV´ IRUPXODWLRQ SUHVHQWV WKH DGYDQWDJH RI
modulating the release and the in vivo stability of doxorubicin, which would otherwise 
leak very rapidly out of the liposomes. It resulted in an even slower release of the 
drug from the delivery system, which was necessary to increase its therapeutic index 
and reduce its side effects on healthy cells. This formulation was shown to be 
efficacious against various cancer cell lines, including DU145 human prostate 
carcinoma and MCF-7 human breast carcinoma [53]. 
 
 Etoposide 
Etoposide, an inhibitor of the enzyme topoisomerase II, is poorly water soluble. In 
order to remediate to this issue, this drug was loaded in micelles made of PAMAM 
(G2) block co-polymer containing poly ( -caprolactone) and PEG [54]. These 
polymeric micelles have been developed to overcome the stability limitations 
generally encountered with the classical micelle structures that may suddenly 
dissociate and cause serious toxicity issues. The covalent binding of the lipophilic 
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poly ( -caprolactone) and the PAMAM dendrimer as the core was shown to increase 
the stability of the polymeric micelle.  
Etoposide was loaded in dendrimer-based polymeric micelles at a loading capacity of 
up to 22% (w/w). In vitro, the treatment of porcine kidney epithelial cells (LLC-PK) 
with this formulation showed a comparable cytotoxicity to that of the drug solution, 
which demonstrated that the drug was released from the polymer micelles and was 
able to exert its cytotoxic effects on cells [54]. 
 
 5-fluorouracil 
To improve its water solubility, the pyrimidine analogue 5-fluorouracil was 
encapsulated in PEGylated PAMAM (G4), improving the drug loading by 12-fold 
compared to that achieved with non-PEGylated dendrimer. Non-PEGylated PAMAM 
dendrimers suffer from drug leakage due to the relative unshielding of the void 
spaces containing the drug and hemolytic toxicity due to the presence of NH2 groups 
on their surface. The coating on the surface of PAMAM dendrimers with PEG can 
therefore increase drug loading and overcome hemolytic toxicity. As a result, 5-
fluorouracil displayed a sustained release from the delivery system over 6 days [55].  
 
 Methotrexate 
To improve its bioavailability and its poor water solubility, methotrexate has been 
encapsulated in PEGylated PAMAM (G3 and G4) dendrimers. As for doxorubicin, the 
encapsulation efficiency of this drug was the highest with PAMAM (G4) and PEG 2000, 
resulting in the encapsulation of 26 methotrexate molecules per dendrimer molecule 
[52].  
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In another study, methotrexate has also been encapsulated in melamine-based 
dendrimers. These types of dendrimers have been shown to be able to solubilize 
hydrophobic drugs and to reduce their organ toxicity without altering their therapeutic 
efficacy. The intraperitoneal injection of the known hepatotoxic drug methotrexate 
loaded in melamine-based dendrimers resulted in a decrease of hepatotoxicity in 
mice, with a 27% decrease of the levels of alanine transaminase compared to those 
obtained with the free drug [56]. 
 
 Paclitaxel 
Like the drugs mentioned above, the therapeutic use of the mitotic inhibitor paclitaxel 
is limited by its poor solubility in water. This problem has been overcome by 
encapsulation of the drug in polyglycerol dendrimers, which led to a drug water 
solubility 400-fold higher than that of the free drug [57].   
 
+RZHYHU WKH ³HQFDSVXODWLRQ RI GUXJV ZLWKLQ WKH GHQGULPHU´ DSSURDFK LV OLPLWHG E\
the very small capacity of the void spaces within the dendrimers and the difficulty to 
effectively control the release of the encapsulated drugs. An alternative delivery 
approach for larger molecules is therefore to conjugate then to the surface of the 
dendrimers.  
 
1.1.2. Conjugation of drugs to the dendrimers  
Anti-cancer drugs can be covalently conjugated to the peripheral groups of the 
dendrimer. Owing to the multifunctional architecture of the dendrimer, many drug 
molecules can be attached to one dendrimer, as well as the targeting moieties for 
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enhanced tumor-delivery specificity. The release of the drug is controlled by the 
degradable chemical bonds linking the drug and the dendrimer.  
Various anti-cancer drugs have been studied as dendrimer-drug conjugates, as 




Cisplatin was conjugated to PAMAM dendrimer (G3.5) (dendrimer-cisplatin: 20-25 wt 
% platinum), which resulted in increased water solubility and slow release of the drug 
[51,58]. The intravenous administration of the conjugate to mice bearing 
subcutaneous B16F10 tumors led to selective accumulation in tumors and anti-tumor 
efficacy, unlike the free drug solution.  The conjugate also showed therapeutic 
efficacy against all the tumors tested, including a platinum-resistant tumor model. 
 
 Doxorubicin 
Doxorubicin was conjugated to one side of a 2,2-bis (hydroxymethyl) propionic acid 
dendrimer (G3), the other side of the dendrimer being PEGylated, to form an 
asymmetric bow-tie dendrimer containing 8-10 wt % doxorubicin [59]. The acyl 
hydrazine linkage used to conjugate the drug to the dendrimer was pH sensitive, thus 
releasing the drug after it reached its target. A single intravenous administration of 
this doxorubicin conjugate in mice bearing subcutaneous doxorubicin-insensitive C-
26 colon carcinoma tumors resulted in complete tumor regression and survival of all 
mice over 60 days. By contrast, no complete tumor regression was observed 
following treatment with the drug solution.   
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 Methotrexate  
 Methotrexate has been conjugated to folic acid- and fluorescein isothiocyanate-
bearing PAMAM dendrimer (G5). This conjugate provided tumor targeting and 
inhibited cell growth of KB cells overexpressing folic acid receptors. By contrast, the 
methotrexate-dendrimer conjugate without folic acid did not succeed in inhibiting the 
growth of these cancer cells [60]. 
In addition, methotrexate was covalently linked to PAMAM (G5) as well, but this 
dendrimer was conjugated to cetuximab instead of folic acid [61]. Cetuximab is a 
monoclonal antibody which exerts its therapeutic effect as an epidermal growth factor 
inhibitor.  Cetuximab-bearing conjugate containing 12.6 molecules of methotrexate 
per unit of dendrimer was tested on rats bearing brain implants of EGFR-expressing 
F98 rat glioma cell line, but unfortunately did not lead to a therapeutic improvement 
compared to the free drug. The median survival times of the rats receiving the 
conjugate, the monoclonal antibody alone or the free drug were respectively of 15, 17 
and 19.5 days, which was not statistically different [61]. This may be due to the fact 
that the conjugation of the drug to PAMAM and a monoclonal antibody may have 
decreased the binding affinity of the drug for the dihydrofolate reductase, resulting in 
a loss of the antifolate activity of the drug. Another possibility is that the drug was not 





1.2. Gene delivery 
The use of dendrimers as delivery systems for nucleic acids has been widely 
investigated for the treatment of cancers. In this review, we will focus on the 
dendrimers used in vivo following intratumoral or intravenous administration, for 
which therapeutic effects have been obtained.   
 
1.2.1. Intratumoral administration 
PAMAM dendrimers have become widely used as non-viral carriers for gene delivery.  
Superfect® PAMAM dendrimer complexed to plasmid DNA encoding herpes simplex 
virus thymidine kinase (HSV-tk) at a dendrimer: DNA weight ratio of 3:1 resulted in 
growth delay [62]. This effect was even accentuated by the fact that the plasmid 
contained Epstein-Barr virus sequences conferring the capability to replicate and stay 
in the nucleus of the transfected cells.   
Another study involved the same Superfect® PAMAM dendrimer, but this time 
complexed to a 36-mer oligonucleotide, which itself complexed the therapeutic 
plasmid DNA encoding the anti-angiogenic peptide angiostatin or the tissue inhibitor 
of metalloproteinase (TIMP)-2 [63]. The intratumoral administration of this 
dendrimer/plasmid/oligonucleotide complex led to growth delay of the tumor. 
In addition, Bai and colleagues [64] developed an arginine-bearing PAMAM 
dendrimer to deliver plasmid DNA encoding human interferon beta to mice bearing 
U87MG brain tumor. Mice treated with intratumoral administration of the dendriplex 




1.2.2. Intravenous administration 
 Polyamidoamine (PAMAM) dendrimer 
Wu and colleagues recently developed a PAMAM dendrimer (G5) with a 
triethanolamine core, able to interact with siRNA to protect it from degradation and 
facilitate gene delivery to the cells [65]. This dendriplex was able to deliver siRNA to 
prostate tumors, thus resulting in gene silencing of the heat shock protein Hsp27 and 
in anti-cancer effects against the tumors [66].  
In another study, Superfect® PAMAM (G5) was complexed to Epstein-Barr virus-
based plasmid vectors carrying the herpes simplex virus-1 thymidine kinase gene for 
suicide gene therapy against cancer in mice [62]. The intravenous administration of 
this complex led to suppression of tumor growth and prolonged survival times of the 
tumor-bearing mice.  
PAMAM dendrimer has been used for co-administration of a therapeutic DNA and an 
anti-cancer drug. This was the case in a study by Han and colleagues, where a 
PEGylated PAMAM carrying doxorubicin was complexed to a plasmid DNA encoding 
human tumor necrosis factor-related apoptosis±inducing ligand (TRAIL) and 
conjugated to the peptide HAIYPRH (T7), a transferrin receptor-specific peptide [67]. 
The peptide-conjugated dendriplex led to an enhanced cellular uptake of DNA and 
accumulation in tumor than the non-targeted complex, in the human liver cancer Bel-
7402 cells overexpressing Tf receptors. This synergistic treatment resulted in a tumor 
decrease in mice compared to the non-modified dendrimer [67]. 
PAMAM dendrimer was also chosen as delivery system for the treatment of glioma 
following intravenous injection. To this end, the PEGylated dendrimer was 
conjugated to Angiopep-2, which can target the low density lipoprotein receptor-
related protein 1 (LRP-1) overexpressed on brain capillary endothelial cells and on 
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glioma cells. Angiopep-2-bearing dendrimer was then complexed to a plasmid DNA 
encoding TRAIL, able to specifically induce cell apoptosis of brain tumors without 
secondary effects to normal cells [68]. The median survival time of the mice following 
intravenous administration of the Angiopep-bearing dendriplex and temozolomide 
was respectively 61 and 49 days, which demonstrated the ability of the dendriplex to 
target the glioma after intravenous administration [68].  
PAMAM dendrimer can also be used in conjunction of magnetic nanoparticles for 
gene therapy of brain tumors.  Han and colleagues conjugated the PAMAM 
dendrimer to magnetic nanoparticles and Tat peptides [69].  This conjugate was then 
complexed to small interfering RNA expression plasmid able to downregulate the 
EGF receptor gene. The intravenous administration of this conjugate to mice bearing 
subcutaneous U251 tumors downregulated the expression of oncoproteins and 
slowed the growth rate of the tumors compared to controls [69].  
 
Polypropylenimine (PPI) dendrimer  
siRNA/PPI complexes were successively caged with a dithiol-containing cross-linker, 
PEG and then conjugated with a synthetic analogue of luteinizing hormone releasing 
hormone (LHRH) peptide to deliver the siRNA specifically to LHRH receptor-positive 
cancer cells [70]. The administration of LHRH-bearing PPI complex resulted in an 
increased siRNA accumulation in tumors, internalization by cancer cells and gene 
silencing. 
LHRH peptide was also used for the cancer specific targeting of PPI dendrimer (G5) 
complexed to superparamagnetic iron oxide nanoparticles (SPION) and siRNA [71]. 
SPION have been widely studied as magnetic resonance imaging (MRI) contrast 
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agents. Their integration to this therapeutic system was intended to allow MRI 
visualization of the disease progression and therapeutic response.  
This targeted delivery system enhanced the anti-cancer efficacy of the drug cisplatin, 
by suppressing the anti-apoptotic defense by siRNA targeted to BCL2 mRNA in mice 
bearing lung cancer xenografts. A result of this treatment was a tumor volume 
decrease by 75% in comparison with controls.  
Dufès and colleagues have demonstrated that the intravenous administration of PPI 
(G3) complexed to plasmid DNA encoding WXPRU QHFURVLV IDFWRU 71)Į XQGHU
control of a tumor-specific promoter resulted in regression of subcutaneous A431 
epidermoid carcinoma and survival of 100% of the mice [72,73]. This treatment 
appeared to be well tolerated, as there was no weight loss compared to controls.  
More recently, Dufès and colleagues demonstrated that a Tf-bearing PPI dendriplex 
resulted in gene expression mainly in the tumors after intravenous administration 
[74]. As a consequence of this improved distribution, the intravenous administration 
of the Tf-bearing PPI dendriplex HQFRGLQJ71)ĮOHGWRDUDSLGDQGVXVWDLQHGWXPRU
regression over one month (90% complete response, 10% partial response on A431 
human epidermoid tumors). It also resulted in tumor suppression for 60% of PC-3 
and 50% of DU145 prostate tumors [75]. In a parallel study by the same group, Tf-
bearing PPI dendriplex encoding p73, a member of the p53 family of transcription 
factors, led to complete tumor suppression for 10% of A431 and B16-F10 tumors and 
long-term survival of the animals [76]. These treatments were well tolerated by the 





CONCLUSIONS & FUTURE PERSPECTIVE 
Dendrimer-based delivery systems have demonstrated to be highly promising 
carriers of therapeutic genes and drugs to the brain and cancer cells.  Until recently, 
the full exploitation of this approach was hampered due to specific delivery and 
safety issues. This problem is now being overcome by the use of targeted strategies 
allowing intravenous delivery of these nanomedicines. Moreover, intensive study on 
dendrimers has provided critical technological advances that will benefit the design of 
³QH[W JHQHUDWLRQ´ GHQGULPHUV 'HQGULWLF QDQRWHFKQRORJ\ HQDEOHV WKH V\QWKHVLV RI
well-defined, globular structures incorporating specific chemical groups tailored for 
increasing the safe and effective delivery of a nucleic acid or a drug to its site of 
action, in a controlled way. For example, the further development of dendrimers with 
environmentally sensitive linkages should improve the drug release from the 
dendrimer. Moreover, the exploitation of new targeting strategies should optimize the 
delivery of nucleic acids and drugs to the brain or tumors, and therefore improve their 
therapeutic efficacy. In addition, the bioactive agents can be entrapped within the 
dendrimer structure, conjugated or complexed to the dendrimer surface, which allows 
a precise tailoring of the properties of the carriers to the specific needs of their cargos 
in terms of solubility, protection against degradation, release and delivery to the site 
of action. More generally, dendrimers are likely to be used in therapeutic strategies 
combining targeting, imaging, diagnostics and therapy, due to their multifunctional 
architecture. Clinical trials using dendrimers in cancer therapy are still pending, but 
dendrimers have already been successfully introduced in the clinic as anti-viral 
agents. Continued research in this area should therefore enable the preparation of 
highly specific, highly efficacious dendrimer-based nanomedicines towards the 
treatment of cancer and brain diseases in the clinic.  
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EXECUTIVE SUMMARY  
Rationale for using dendrimers for brain delivery and cancer therapy: 
 The use of promising novel therapeutics is limited by their inability to 
specifically reach the brain and tumors after intravenous administration, 
resulting in toxicity to healthy tissues.  
 Dendrimers are emerging as potential non-viral vectors for efficiently 
delivering drugs and nucleic acids to the brain and cancer cells. 
 They are well-defined, globular structures incorporating specific chemical 
groups tailored for increasing the safe and effective delivery of a nucleic acid 
or a drug to its site of action, in a controlled way. 
 The bioactive agents can be entrapped within the dendrimer structure, 
conjugated or complexed to the dendrimer surface, which allows a precise 
tailoring of the properties of the carriers to the specific needs of their cargos in 
terms of solubility, protection against degradation, release and delivery to the 
site of action. 
 
Applications of dendrimers for brain delivery: 
 Dendrimers can deliver drugs and nucleic acids to the brain by exploiting the 
specific transport systems expressed on the blood-brain barrier 
 Various dendrimers targeting the transferrin receptor, the low density 
lipoprotein receptor-related proteins, the glucose transporter GLUT-1 and the 
leptin receptors have been developed. 
 Brain uptake of drugs and nucleic acids carried by targeted dendrimers was 
increased compared to non-targeted dendrimers.  
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Applications of dendrimers for cancer therapy: 
 Dendrimers can either non-covalently encapsulate anti-cancer drugs in the 
void spaces within the dendritic structure, or carry them via covalent 
conjugation to the surface groups.  A wide range of anti-cancer drugs have 
been studied as dendrimer cargos. 
 Water solubility and therapeutic efficacy against tumors have been enhanced 
for the anti-cancer drugs carried by dendrimers.  
 Dendrimers have been used for the delivery of siRNA, plasmid DNA, alone or 
associated to anti-cancer drugs, to the tumors following intratumoral or 
intravenous administration. 
 Tumor regression has been obtained following intravenous administration of 
therapeutic nucleic acids carried by targeted dendrimers. 
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Figure 1. Schematic 2D representation of a dendrimer. 
 
Figure 2. Schematic representation of dendrimer-drug/nucleic acid delivery systems. 
 
Figure 3. Chemical structure of polyamidoamine (PAMAM) (G3) and 
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